Gilead Sciences
GILD
Performance
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and delivering medicines across virology, oncology, and inflammation to improve global health. The company emphasizes HIV, viral hepatitis, liver disease, cancer, and inflammatory conditions, with a pipeline spanning multiple therapeutic areas and a global presence. It highlights investments in research, patient access, and responsible corporate initiatives to advance health equity worldwide. Headquartered in Foster City, California, Gilead operates internationally to bring breakthrough therapies to patients around the world.
Recent News
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
Regulatory Actions for April 30, 2026
WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
FDA Approves Hepcludex, First Treatment for Chronic Hepatitis D
Re: The Power of the Markets: The Scandal that Keeps on Taking
Vivatides Gets $54M; Wegovy Drops Cold Chain in EU; Gilead Takes Kymera Option
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102
#58798
Fidelity and Vanguard Freeze SPLC Grants After Federal Indictment
FDA Sends Letters to 2,200 Sponsors, Demanding Public Trial Results
Gilead Sciences Completes Tubulis Acquisition for $5bn
Hepatitis Vaccine Uptake Declining, Liver Disease Could Increase
Flagship CEO Calls Out Attacks on Science, Warns of China Dominance
Gilead Price Target Raised to $175 From $171 at Morgan Stanley
Market Wrap: Caution Finally Hits ASX to End Three-Week Winning Streak
STAT+: Pharmalittle: We’re Reading About Replimune Drug Getting Third Try at FDA Approval, a Pfizer Deal in China, and More
FDA’s CRL Transparency Policy Is Boosting Biopharma Accountability
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Gilead's Trodelvy Wins CHMP Positive Opinion for First‑Line Metastatic Triple‑Negative Breast Cancer
First Non-INSTI, Tenofovir-Free Regimen DOR/ISL Gains FDA Approval for HIV
Why Owning the Learning Loop Matters More Than Owning the Lab
Pharmaceutical Executive Daily: Wegovy HD Now Available in the U.S.
What Makes Veeva Systems Inc (VEEV)’s Future Bright?
FDA Grants Accelerated Approval to Gilead’s Hepcludex, First U.S. HDV Therapy
Yield-Hungry Investors Bet on Credit as Government Debt Sours
STAT+: AIDS Group Sues Trump Administration over Undisclosed Agreement with Gilead
CMS's Medicare Price Negotiations Start Round Three
Top Biotech Deals in March 2026
Merck Steps up as 'Meaningful Competitor' To Gilead with HIV Pill Approval
FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug
What Does 17 Pharma MFN Deals Are Underneath the Press Releases: The Real Primary Source Stack, the GLP1 Numbers, TrumpRX Plumbing, and Where the New Adjudication Layer Gets Monetized
Salesforce’s New COO Leads AI‑Driven Turnaround, Internal Chart Shows
FDA’s 2027 Budget Proposes Permanent Rare Disease Vouchers, Easier Entry to Clinic
With Gilead’s Reasonableness Standard, Side Effects May Vary
Tech Sector Falters While Healthcare Stocks Soar: Dissecting Today's Market Movements
FDA Clears Merck's First Once‑Daily Oral HIV Pill
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
Gilead Shows Belief in Its Partner’s Cancer Treatment with $7.8 Billion Buyout
FDA Oncology Roundup: AbbVie’s Rare Cancer Approval, AstraZeneca in Breast Cancer Limbo
Merck’s PD-1/VEGF Data Star in Stacked Lineup of AACR ‘26 Data Reveals
AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer
From AMD To Disney, The Wall Street Week Ahead Is Packed
CMS Picks Lilly’s Trulicity, Gilead's Biktarvy for Third Round of Medicare Negotiations
STAT+: Gilead to Buy Cancer Biotech Tubulis for More than $3 Billion
Kymera Therapeutics Inc (KYMR) Q1 2026 Earnings Call Transcript
J&J’s Duato Makes 358 Times His Median Employee; Vertex CEO Makes Just 80 Times
Weekly Wrap: Market Steps Back From the Brink with a Rise
FDA Grants First U.S. Approval for Bulevirtide, Gilead’s Hepatitis D Therapy
Recent Deals
Gilead Sciences to Acquire Tubulis, Adding ADC Platform to Oncology Pipeline
Gilead Sciences Completes Tubulis Acquisition for up to $5bn
Gilead Sciences to Acquire Ouro Medicines in over $2 Billion Buyout
Gilead Sciences to Acquire Arcellx for up to $7.8B
Gilead Acquires Global Rights to Genhouse Bio's Oral Cancer Drug for $80M
Gilead to Acquire Tubulis for ~$5B